STOCK TITAN

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) management team to participate in investor conferences, including TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Barclays Global Healthcare Conference. Live webcasts and replays available on the company's website.
Positive
  • None.
Negative
  • None.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:

  • TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 1:30 PM ET in Boston, MA
  • Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 2:40 PM ET in Miami Beach, FL
  • Barclays Global Healthcare Conference on Wednesday, March 13, 2024 at 8:00 AM ET in Miami Beach, FL

Live webcasts will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. All webcast replays will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Norway, Singapore, Switzerland, Taiwan, The United Kingdom, and the United States. For more information, visit https://www.deciphera.com/ and follow us on LinkedIn and X (@Deciphera).

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals management team will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 1:30 PM ET in Boston, MA.

You can watch the live webcasts of the investor conferences on the 'Events and Presentations' page in the 'Investors' section of Deciphera Pharmaceuticals' website at https://investors.deciphera.com/events-presentations.

The webcast replays will be archived on Deciphera Pharmaceuticals' website for 90 days following the presentation.
Deciphera Pharmaceuticals Inc

NASDAQ:DCPH

DCPH Rankings

DCPH Latest News

DCPH Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Waltham

About DCPH

deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.